At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Telotristat etipratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
In Brief
A Phase 2 clinical trial evaluating Telotristat etiprate for Carcinoid Syndrome. Completed, enrolled 15 participants across 10 sites in 2 countries.
Detailed Summary
The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Syndrome
CountriesGermany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartJun 2010
Primary CompletionFeb 2014
TodayJul 2026
First PostedApr 15, 2010
Enrollment StartJun 15, 2010
Primary CompletionFeb 12, 2014
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.2 years ago
Interventions
Telotristat etipratedrug
Telotristat etiprate capsules orally three times daily.